Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Want to cut your energy bills? Here’s how five experts are doing it 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SEATTLE and SOUTH SAN FRANCISCO, March 01, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth quarter and year end 2016 financial results after the close of U.S. financial markets on Tuesday, March 7, 2017. Immune Design management will host a webcast and conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on March 7, 2017 to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for 90 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 70907410.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVex® and GLAAS®. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.
Media Contact Julie Rathbun Rathbun Communications [email protected] 206-769-9219 Investor Contact Shari Annes Annes Associates [email protected] 650-888-0902
